Watch this company for free updates
Simply enter your email address below and we will send you an email when the company files any documents or there is a change to their credit report.
We require your email address in order to send you alerts by email. You can unsubscribe at any time.
Thank you, you are now watching this company.
You will receive email updates when this company's information changes.
You can choose which alerts you receive and can unsubscribe at any time.
Unlock NATIONAL CONFIDENTIAL ENQUIRY INTO PATIENT OUTCOME AND DEATH's Credit Report?
Unlock The Full Report
- Credit score, financials and risk data
- Directors, shareholders and ownership
- CCJs, payment behaviour and filing history
- 5 official Companies House documents
- Instant download and online viewing
- Email alerts for key changes
- Personal monitoring dashboard
Upgrade to Lite
- 5 credit reports
- 100 accounts downloads
- 100 accounts exports
Your plan will start immediately and the time remaining on your existing plan will be refunded
Yes, upgrade to LiteNATIONAL CONFIDENTIAL ENQUIRY INTO PATIENT OUTCOME AND DEATH
GROUND FLOOR ABBEY HOUSE, 74-76 ST. JOHN STREET, LONDON, EC1M 4DZ
Buy Report - £20
Download PDF
Unlock the Full Company Report
- ✓ Check whether this company is legitimate
- ✓ See if this company is likely to run into financial trouble
- ✓ Find out who owns and runs the company
- ✓ Avoid risky business relationships
- ✓ Get instant updates if anything important changes
- ✓ Access official company documents for free
NATIONAL CONFIDENTIAL ENQUIRY INTO PATIENT OUTCOME AND DEATH
Private Limited by guarantee without Share Capital Exempt from using Limited
Active - Accounts Filed
08 February 1995
86210 General medical practice activities - General medical practice activities
Available to 03 Sep 2025. Next accounts due by 31 Dec 2026
Is NATIONAL CONFIDENTIAL ENQUIRY INTO PATIENT OUTCOME AND DEATH in debt to you?
Don't write it off. As exclusively featured on Can't Pay? We'll Take It Away!, DCBL provides a nationwide service recovering over £85 million annually.
Our unique "One Solution" works seamlessly with DCB Legal, managing debt recovery from the first letter through to High Court enforcement.
We act fast to protect your cash flow and recover what you're owed. Recover your debt with the UK's experts.
Current Directors & Secretaries
For a full in-depth analysis on each of these directors, click any of the links below
| Name | Role | Date Of Birth | Appointed |
|---|---|---|---|
| Mr James Alan Harvey | Director | ||
| Dr Paul Charles Butterworth | Director | ||
| Dr Kathleen Ann Richmond | Director | ||
| Professor Zudin Amilka Puthucheary | Director | ||
| Dr Frances Mary Healey | Director | ||
| Professor Namita Kumar | Director | ||
| Dr Suzannah Claire Lishman | Director | ||
| Dr Peta Jane Greaves | Director | ||
| Dr Marisa Mason | Company Secretary |
Previous Directors & Secretaries
Mortgages and Charges
Total Outstanding
2
Total Satisfied
0
| Type | Created | Registered | Persons Entitled | Status |
|---|---|---|---|---|
| Rent Deposit Deed | Venaglass Limited | OUTSTANDING | ||
| Rent Security Deposit Deed | Commerzbank Aktlengesellschaft | OUTSTANDING |
Key Financials
| Accounts | |||||
|---|---|---|---|---|---|
| Cash | £823,306.00 | £1,115,772.00 | £1,174,480.00 | £1,264,869.00 | £1,091,609.00 |
| Net Worth | £1,403,151.00 | £1,544,698.00 | £1,691,692.00 | £1,694,229.00 | £1,515,571.00 |
| Total Current Liabilities | £90,289.00 | £120,351.00 | £31,329.00 | £171,666.00 | £147,625.00 |
| Total Current Assets | £1,190,472.00 | £1,463,842.00 | £1,540,693.00 | £1,641,208.00 | £1,447,366.00 |
Frequently Asked Questions about NATIONAL CONFIDENTIAL ENQUIRY INTO PATIENT OUTCOME AND DEATH
Detailed answers about NATIONAL CONFIDENTIAL ENQUIRY INTO PATIENT OUTCOME AND DEATH, including incorporation, status, business activity, and accounts information.
When was NATIONAL CONFIDENTIAL ENQUIRY INTO PATIENT OUTCOME AND DEATH founded?
NATIONAL CONFIDENTIAL ENQUIRY INTO PATIENT OUTCOME AND DEATH was officially incorporated on 08 February 1995 and is registered under company number 03019382. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is NATIONAL CONFIDENTIAL ENQUIRY INTO PATIENT OUTCOME AND DEATH?
Private Limited by guarantee without Share Capital Exempt from using Limited. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. For example, a private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of NATIONAL CONFIDENTIAL ENQUIRY INTO PATIENT OUTCOME AND DEATH?
NATIONAL CONFIDENTIAL ENQUIRY INTO PATIENT OUTCOME AND DEATH's current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does NATIONAL CONFIDENTIAL ENQUIRY INTO PATIENT OUTCOME AND DEATH do?
NATIONAL CONFIDENTIAL ENQUIRY INTO PATIENT OUTCOME AND DEATH operates in the following sector: 86210 General medical practice activities - General medical practice activities . This provides insight into the company’s primary business activities and industry focus. Knowing the SIC code and description is useful for market research, assessing competitors, and understanding potential business risks.
What is NATIONAL CONFIDENTIAL ENQUIRY INTO PATIENT OUTCOME AND DEATH's registered address?
The registered office address of NATIONAL CONFIDENTIAL ENQUIRY INTO PATIENT OUTCOME AND DEATH is 74-76, St. John Street, London, Islington, EC1M 4DZ. This is the official address filed with Companies House for legal and statutory correspondence.
Is NATIONAL CONFIDENTIAL ENQUIRY INTO PATIENT OUTCOME AND DEATH financially stable?
Based on the latest accounts up to 03 Sep 2025, NATIONAL CONFIDENTIAL ENQUIRY INTO PATIENT OUTCOME AND DEATH has filed financial statements showing its assets, liabilities, and overall trading performance. The next accounts are due by 31 Dec 2026. Reviewing these accounts helps assess the company’s financial stability, creditworthiness, and risk profile, which is crucial for investors, suppliers, and potential business partners.